NCT05164978

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

DEP Combine With PD-1 Antibody as an Treatment for EBV Associated Hemophagocytic Lymphohistiocytosis (HLH)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to investigate the efficacy and safety of DEP (liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for EBV associated hemophagocytic lymphohistiocytosis.

Detailed description

PD-1 antibody added to the DEP regimen （with or without asparaginases） in EBV-HLH,

Conditions

• Hemophagocytic Lymphohistiocytosis

Interventions

Type	Name	Description
DRUG	DEP combine with PD-1 antibody	Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4

Timeline

• Start date: 2021-05-01
• Primary completion: 2023-01-01
• Completion: 2023-01-01
• First posted: 2021-12-21
• Last updated: 2022-03-02

Locations

1 site across 1 country: China